LinkMed logo
sp
sp divider
The LinkMed portfolio consists of a number of life science companies, several of which are nearing the commercialization phase, while others are already selling their products or services. Between them, these companies account for more than 50 different projects in a wide range of therapeutic areas – from HIV and cancer to eye disease and allergies.
COMPANIES IN SEVERAL SECTORS
LinkMed has created a portfolio of twelve companies, four in drug development and biotechnology and eight in diagnostics and medical technology
MANY COMPANIES, LOWER RISKS
By investing in several companies, we spread risks and reduce our exposure to the development in individual projects. Our goal is to continually develop and manage between 15 and 20 portfolio companies. Therefore, we plan to invest in several new companies in the coming years.
AbSorber

For successful transplantations and beyond

Operations: AbSorber develops products that facilitate successful transplantations. The company’s first product, the trans-plantation test XM-ONE® identifies antibodies that play a key role in causing rejection subsequent to transplanta-tion. The product has already been approved for sales in Europe and received clearance for the U.S. market in August 2008. The company is also developing a pa-tented AB0 column for transplantations between people with different blood groups and an ABO diagnostic test that measures the occurrence of blood group antibodies.

Sektor: Drug development and biotechnology

Therapeutic area: Transplantation

CEO: Anders Karlsson

Chairman: Jan Ericsson

Venture manager: Ingemar Lagerlöf

Ownership stake: 98.0%

Address: AbSorber AB
Box 7710
Drottninggatan 33
SE-103 95 Stockholm
Sweden

www.absorber.se

Back